Keyword: Guardant Health

Guardant blood test tracks MSI on par with tissue biopsy: study

by Conor Hale

Monday, August 5, 2019

Guardant Health’s blood test could provide an easier way to predict a cancer patient’s response to immunotherapy across multiple solid tumors.

by Conor Hale

Monday, April 1, 2019

A retrospective study of Resolution’s blood test and Guardant360 found that it was able to detect a greater number of actionable mutations in NSCLC.

by Conor Hale

Thursday, March 28, 2019

Guardant Health has moved to acquire Bellwether Bio, which focuses on early cancer diagnostics that tap into the epigenomics of cell-free DNA.

by Conor Hale

Thursday, February 28, 2019

A head-to-head study found Guardant’s lung cancer blood test delivered similar results much faster and with more accuracy in first-line NSCLC.

by Amirah Al Idrus, Conor Hale, Ben Adams

Friday, January 11, 2019

What can you expect from M&A, IPOs and VC raises in 2019? We spoke to execs at the J.P. Morgan Healthcare Conference this week to find out.

by Conor Hale

Tuesday, January 8, 2019

SAN FRANCISCO—Guardant Health has launched a new epigenetic liquid biopsy test for researchers aimed at spotting cancer in its early stages.

by Conor Hale

Friday, December 14, 2018

AstraZeneca has tapped Guardant Health to develop blood-based companion diagnostics for its cancer treatments Tagrisso and Imfinzi.

by Conor Hale

Monday, September 10, 2018

In its IPO filing, Guardant Health disclosed it had received a cyberattack, with hackers accessing the personal information of about 1,100 patients.

by Conor Hale

Thursday, September 6, 2018

Cancer blood test maker Guardant Health plans to go public, filing an IPO on the Nasdaq using the symbol GH.

by Conor Hale

Wednesday, June 6, 2018

SoftBank is considering a $150 million investment in siteless trial runner Science 37, the latest in a string of biotech deals, according to reports.

Subscribe to FierceBiotech to get industry news and updates delivered to your inbox.